Research table: Elacestrant (Orserdu) for metastatic breast cancer treatment

This summary table contains detailed information about research studies. Summary tables are a useful way to look at the science behind many breast cancer guidelines and recommendations. However, to get the most out of the tables, it’s important to understand some key concepts. Learn how to read a research table.

Introduction: Selective estrogen receptor degraders (SERDs) are a type of hormone therapy. These anti-estrogen drugs bind to the estrogen receptor in a tumor cell. They cause the receptor to be broken down by the cell.

Some SERDs are in pill form (taken orally).

The oral SERD elacestrant (Orserdu) is used to treat hormone receptor-positive, HER2-negative metastatic breast cancers that have an ESR1 tumor gene mutation and have been treated with hormone therapy in the metastatic setting. (The ESR1 mutation is in the genes of the breast cancer cells, not the genes of the person.)

All hormone receptor-positive, HER2-negative metastatic breast cancers should be tested for ESR1 tumor gene mutations.

Learn more about elacestrant and treatment for metastatic breast cancer.

Learn about the strengths and weaknesses of different types of studies.

Study selection criteria: Randomized clinical trials with 100 or more participants with hormone receptor-positive, HER2-negative metastatic breast cancer that had an ESR1 tumor gene mutation.

Study

Study Population
(number of participants)

Drug(s) Used

Objective Response Rate-Percent who Responded to Treatment
(95% CI)

Overall Survival
(95% CI)

Randomized clinical trials

EMERALD trial [1]

228

Elacestrant

7% NS

Overall survival at 1 year:
83%*

   

Fulvestrant, anastrozole, letrozole or exemestane alone

5% NS

Overall survival at 1 year:
74%*

NS = No statistically significant difference between the 2 treatment groups

* Statistically significant difference between the 2 treatment groups.

References

  1. Bidard FC, Kaklamani VG, Neven P, et al. Elacestrant (oral selective estrogen receptor degrader) versus standard endocrine therapy for estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: results from the randomized phase III EMERALD Trial. J Clin Oncol. 40(28):3246-3256, 2022.

Updated 09/28/23